OTCM
RGBP
Market cap3.35bUSD
May 26, Last price
2.00USD
Name
Regen BioPharma Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
90.41%
Rev. gr., 5y
16.55%
Revenues
237k
+0.00%
Net income
-1m
L+90.79%
CFO
-384k
L-44.66%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Regen BioPharma, Inc. is a company dedicated to advancing regenerative medicine within the United States. It actively researches and identifies small molecule compounds designed to modulate the NR2F6 gene. This modulation is strategically aimed at activating immune cells for oncology treatments and suppressing them for autoimmune conditions. Its therapeutic pipeline and product development are currently in their initial phases. Established in 2012, the firm operates from its headquarters in La Mesa, California.
Key people
Todd S. Caven
Chief Financial Officer, Director · since 2019
Legal address
C/O Resident Agents of Nevada, Inc.
711 South Carson Street
Suite 4
Carson City, NV 89701
US
711 South Carson Street
Suite 4
Carson City, NV 89701
US
Headquarters
4700 Spring Street
Suite 304
La Mesa, CA 91942
US
Suite 304
La Mesa, CA 91942
US
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT |